{"id":"W1833759296","doi":"10.1038/80516","title":"Encephalitogenic potential of the myelin basic protein peptide (amino acids 83–99) in multiple sclerosis: Results of a phase II clinical trial with an altered peptide ligand","year":2000,"lang":"en","type":"article","venue":"Nature Medicine","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":826,"is_retracted":false,"has_abstract":false,"ca_institutions":"Montreal Neurological Institute and Hospital","funders":"","keywords":"Myelin basic protein; Multiple sclerosis; Peptide; Myelin; Immunotherapy; Immunology; Ligand (biochemistry); Medicine; Peptide vaccine; Magnetic resonance imaging; Antigen; Biology; Internal medicine; Immune system; Epitope; Biochemistry; Central nervous system; Receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08052038373286932,"score_gpt":0.369205776705015,"score_spread":0.2886853929721457,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}